Azithromycin plus chloroquine
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Asymptomatic Parasitemia In Pregnancy
Conditions
Asymptomatic Parasitemia In Pregnancy
Trial Timeline
Mar 1, 2011 → Oct 1, 2013
NCT ID
NCT01103713About Azithromycin plus chloroquine
Azithromycin plus chloroquine is a phase 3 stage product being developed by Pfizer for Asymptomatic Parasitemia In Pregnancy. The current trial status is terminated. This product is registered under clinical trial identifier NCT01103713. Target conditions include Asymptomatic Parasitemia In Pregnancy.
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01103713 | Phase 3 | Terminated |
| NCT00282919 | Phase 2 | Completed |
Competing Products
2 competing products in Asymptomatic Parasitemia In Pregnancy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Verinurad + Febuxostat + Dapagliflozin | AstraZeneca | Phase 2 | 35 |
| RDEA3170 + Febuxostat + Benzbromarone | AstraZeneca | Phase 1/2 | 32 |